InVivoPlus anti-mouse CTLA-4 (CD152)

Catalog number: BP0164_100mg
Brand: Bio X Cell
Packing: 100 mg
Other sizes: Other sizes available
Price: € 3522.00
Expected delivery time: 7 days
Quantity:

Product specifications for - InVivoPlus anti-mouse CTLA-4 (CD152)

Promotion: 
Promotion: The price displayed is only for academic or non-profit organizations. Please contact our helpdesk for regular prices.
Overview: 
Product group: Antibodies
Category: Primary Antibodies
Application: Neutralisation/Blocking
Species: Mouse
Host: Mouse
Clonality: Monoclonal
Isotype: IgG2b
Properties: 
Molecular weight: 150 kDa
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352203
Concentration: 2-10 mg/ml
Scientific information: 
Clone ID: 9D9
Related products: 
Related products: Recommended Isotype Control(s): InVivoPlus mouse IgG2b isotype control (BP0086)
Recommended Dilution Buffer: InVivoPure pH 6.5 Dilution Buffer (IP0065)
Additional information: 
Synonyms: 9D9; BP0164; CTLA4 / CD152; CTLA4; IDDM12; GSE; GRD4; CTLA-4; CELIAC3; CD152; CD; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte protein 4; cytotoxic T-lymphocyte antigen 4; cytotoxic T lymphocyte associated antigen 4 short spliced form; celiac disease 3; CD152 isoform; cytotoxic T-lymphocyte-associated protein 4; BioXCell
Zippelius A, Schreiner J, Herzig P, Müller P. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. 2015;3(3):236-44. Read more
Dai M, Yip YY, Hellstrom I, Hellstrom KE. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res. 2015;21(5):1127-38. Read more
Müller P, Martin K, Theurich S, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014;2(8):741-55. Read more
Condamine T, Kumar V, Ramachandran IR, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest. 2014;124(6):2626-39. Read more
Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res. 2014;2(2):142-53. Read more
Wei H, Zhao L, Li W, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS ONE. 2013;8(12):e84927. Read more
Bulliard Y, Jolicoeur R, Windman M, et al. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210(9):1685-93. Read more
Dai M, Wei H, Yip YY, et al. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother. 2013;36(4):248-57. Read more
Hooijkaas A, Gadiot J, Morrow M, Stewart R, Schumacher T, Blank CU. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology. 2012;1(5):609-617. Read more
Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17(9):1094-100. Read more